As has been previously shown, the lack of immune surveillance plays a major role in the unchecked proliferation of Epstein-Barr virus (EBV)-infected B cells in the pathogenesis of B-cell post-transplant lymphoproliferative disorders. We hypothesised that the lack of immune surveillance should possibly also affect T cells, and this should lead to subsequent emergence of T-cell clones. The presence of both B-and T-cell clones in post-transplant lymphoproliferative disorders samples has rarely been demonstrated in the past. We systematically evaluated 26 B-cell post-transplant lymphoproliferative disorder, 23 human immune deficiency virus-associated B-cell lymphoma and 10 immune-competent diffuse large B-cell lymphoma samples for B-and T-cell clonality (polymerase chain reaction and heteroduplex analysis using BIOMED-2 protocol), T-cell subsets (immunohistochemistry) and EBV association (in situ hybridisation using EBER). One-half of B-cell posttransplant lymphoproliferative disorders showed evidence of monoclonal T-cell expansion, and among the T cells present in the tissue samples, CD8-positive cells predominated. Although 9/13 (69%) B-cell posttransplant lymphoproliferative disorders with the presence of monoclonal T-cell population had a CD4:CD8 ratio of r0.4, 0/13 of the cases without monoclonal T-cell expansion had a ratio r0.4 (P ¼ 0.002). Only 2/26 (8%) demonstrated significant cytological atypia in the CD3/CD8-positive cells. There was no association between EBV and presence of T-cell clones. T-cell clones were not identified in lymphomas other than B-cell post-transplant lymphoproliferative disorders. Among 53.8% cases of EBV-positive B-cell post-transplant lymphoproliferative disorders with associated clonal expansion of T-cells tested, none had EBV-positive T cells. We conclude that half of B-cell post-transplant lymphoproliferative disorders are associated with clonal expansion of CD8-positive T cells, most of which do not amount to the coexistence of a T-cell post-transplant lymphoproliferative disorders.
Post-transplant lymphoproliferative disorders are similar to other immunodeficiency-related lymphomas in some aspects: an overwhelming majority are derived from B cells; a far higher proportion are nonHodgkin's lymphomas (as compared with classical Hodgkin's lymphoma); they originate usually in extranodal sites but rarely affect skin; and behave aggressively and frequently harbour the EpsteinBarr virus (EBV) genome. 1, 2 Although most are highgrade B-cell non-Hodgkin's lymphomas, a few are classical Hodgkin's lymphomas. Rare cases have also been shown to be either of T-or NK-cell lineages. T-cell neoplasms constitute 10-15% of all post-transplant lymphoproliferative disorders and about 75% of T-cell post-transplant lymphoproliferative disorders have been shown to be negative for EBV and to behave more aggressively. [1] [2] [3] [4] [5] Posttransplant lymphoproliferative disorders harbouring both B-and T-cell clones in the same patient are extremely rare and there are only a few cases reported in the literature so far. [5] [6] [7] [8] [9] [10] [11] [12] [13] EBV plays an important role in driving the proliferation ( Table 1) .
As has been shown previously, the lack of immune surveillance plays a major role in the proliferation of unchecked EBV-infected B cells in the pathogenesis of post-transplant lymphoproliferative disorders, with subsequent development of B-cell lymphoproliferation. 14 We hypothesised that the lack of immune surveillance should possibly also affect T cells, and this should lead to subsequent emergence of T-cell clones. From the previous literature, it appears that post-transplant lymphoproliferative disorders, which demonstrate both B-and T-cell clones, are a rare phenomenon. To test whether this was a more frequent phenomenon, we systematically evaluated a relatively large cohort of B-cell post-transplant lymphoproliferative disorders for the presence of expanded T-cell clones. We have compared B-cell post-transplant lymphoproliferative disorders with human immunodeficiency virus (HIV)-associated aggressive B-cell lymphomas and diffuse large B-cell lymphomas in the immunecompetent individuals. We further attempted to characterise the clonal T cells present in the B-cell post-transplant lymphoproliferative disorders and to evaluate the impact of EBV association with the presence or absence of T-cell clones.
Materials and methods

Selection of Cases
We analysed tumour samples from 26 B-cell posttransplant lymphoproliferative disorders, 24 HIVassociated aggressive B-cell lymphomas and 10 diffuse large B-cell lymphomas in the immunecompetent individuals for B-and T-cell clonality. Ten samples of reactive lymph nodes and 10 samples of DNA from normal peripheral blood mononuclear cells were also tested.
Tissue Microarray
Tissue microarrays were constructed with 2-3 representative 1-mm tissue cores from each case using a manual tissue arrayer. Serial 2-mm-thick sections were cut from tissue microarray blocks.
Immunohistochemical Staining
The slides were stained with antibodies to CD45, CD20, CD30, CD15, CD10, CD3, CD4, CD8, BCL2, BCL6, MUM1 and CD138 using standard procedures on BOND-MAX automated immunohistochemistry system (Leica Microsystems, New Castle, UK).
In Situ Hybridisation mRNA in situ hybridisation with EBER, k and l probes was carried out using BOND-MAX automated in situ hybridisation system (Leica Microsystems). The system employs fluorescein-conjugated oligonucleotide probes. Probe hybridisation is followed by the application of anti-fluorescein antibody and other procedures leading to signal detection as suggested by the manufacturer.
Combined Immunohistochemistry and In Situ Hybridisation
In situ hybridisation using the EBER probe and with diaminobenzidine as the chromogen was performed on paraffin sections using the Bond immunostainer according to the manufacturer's protocol. This was followed by immunohistochemistry for CD3 using Bond polymer AP Red detection kit (Leica Microsystems).
Polymerase Chain Reaction
DNA was extracted from formalin-fixed paraffinembedded tissues using a commercially available kit (DNeasy Blood & Tissue Kit; Qiagen, Crawley, West Sussex, UK). Briefly, two 15-mm sections were cut and placed in 1.5 ml Eppendorf tubes. Blades were changed in between the samples to avoid cross-contamination. Sections were deparaffinised and then incubated with proteinase K and lysis buffer according to the Qiagen protocol in a shaking water bath at 551C overnight. The remaining steps were according to the manufacturer's protocol leading to the elution of DNA. The concentration of the DNA obtained was measured using the Nanodrop 1000 spectrophotometer. A multiplex polymerase chain reaction (PCR) for control genes was performed to ascertain the adequacy and the quality of DNA using BIOMED primers 15 (Invitrogen, Paisley, UK). Cases that had amplicons of 4200 bp in size were used subsequently for clonality assessment.
All cases were investigated for T-cell receptor gene rearrangements (TCRb, TCRg and TCRd gene rearrangements) and for B-cell receptor gene rearrangements (IGH, IGk and IGl gene rearrangements). The BIOMED-2 PCR protocol was followed with minor modifications. 16 The test was performed in duplicates. For every run, a positive control (DNA from a known positive case, which had earlier demonstrated a clear monoclonal PCR product), a negative DNA control and a negative control (master mix with no DNA) were used. The Perkin Elmer GeneAmp PCR system 2400 thermal cycler was used to carry out all PCR reactions. The samples were initially denatured at 951C for 10 min, followed by 35 cycles of amplification of 45 s at 951C, 30 s at 641C and 45 s at 721C, and the programme was then ended with final extension at 721C for 10 min. All PCR products were subjected to electrophoresis in 2% agarose gel for 45-60 min at 100 V and visualised using an ultraviolet gel imager (Alpha Innotech, Gabon, UK).
Once the presence of products was confirmed, heteroduplex analysis was carried out according to the standardised protocol of BIOMED-2. Briefly, PCR products were denatured at 951C for 5 min, and then re-annealed at 41C for 60 min. Seven microlitres of each product were mixed with 2 ml non-denaturing Blue/Orange loading dye, 6 Â (Promega), and then subjected to electrophoresis in a 10% polyacrylamide Novex TBE Precast gel (Invitrogen) using (XCell SureLockt Mini-Cell; Invitrogen) in 1 Â diluted-TBE running buffer (10 Â ; Invitrogen) for 1 h at 100 V. The products were visualised through staining with Sybersafe in TBE buffer for 10 min followed by washing twice in TBE buffer and then imaged using an ultraviolet gel imager (Alpha Innotech).
Analysis of Gene Rearrangements
The results were analysed as being: monoclonal, when 1-2 dominant bands within the expected size range were identified either alone or seen with a background of multiple weaker bands or smear; oligoclonal, when there were three or more bands, which may be superimposed on a polyclonal background; polyclonal, when there were either a ladder of bands 10-20 or a smear over the expected size range; and no signals when no products or only weak bands outside the expected size range were identified. 17 
Statistical Analysis
Statistical correlations were performed using w 2 tests to evaluate the differences between cases with the presence or absence of T-cell clones and EBV association, and between the presence or absence of T-cell clones and cases having a CD4:CD8 ratio of r0.4 or 40.4, using the SPSS 17.0 software. All tests were two-sided and a P-value less than 0.05 was considered significant.
Results
Clinical Characteristics
All post-transplant lymphoproliferative disorders samples were classified according to the current WHO classification. 18 Among B-cell post-transplant lymphoproliferative disorders, 17 (66%) were men. The age ranged from 2 to 80 years, with a median age of 48 years. Among HIV-associated aggressive B-cell lymphomas, 22 (92%) were men. The age ranged from 26 to 66 years, with a median age of 41 years. Five (50%) of the diffuse large B-cell lymphomas in the immunecompetent individuals were men and the age ranged from 27 to 83 years, with a median age of 43 years.
Morphology and Phenotype
Among B-cell post-transplant lymphoproliferative disorders samples, 1, 9 and 16 were classified as early lesions (plasmacytic hyperplasia), polymorphic post-transplant lymphoproliferative disorders and monomorphic B-cell post-transplant lymphoproliferative disorders, respectively. Among HIV-associated aggressive B-cell lymphomas, 9, 14 and 1 were Burkitt's lymphoma, diffuse large B-cell lymphoma and polymorphic post-transplant lymphoproliferative disorders-like lesion, respectively.
B-cell Clonality Testing by Investigating for IGH, IGj and IGk Gene Rearrangements
Among B-cell post-transplant lymphoproliferative disorders, 22/26 (84.6%) showed monoclonal B-cell expansion (15/16 monomorphic B-cell posttransplant lymphoproliferative disorders and 7/9 polymorphic post-transplant lymphoproliferative disorders). The case of plasmacytic hyperplasia and 2/9 polymorphic lesions showed polyclonal B-cell expansion ( Table 2 ). The case of monomorphic B-cell post-transplant lymphoproliferative disorders that did not show evidence of monoclonal B-cell expansion by PCR was k-light chain restricted on in situ hybridisation, which was used as a surrogate MC  10  PM  PC  PC  PC  PC  PC  PC  PC  NA  PC  PC  PC  PC  PC  PC  PC  11  PM  -PC  MC  --OC  -DOC  PC  PC  PC  PC  PC  MC  DOC  12  PM  --PC  NA  PC  PC  -PC  PC  PC  PC  PC  PC  PC  PC  13  MM-DLBCL  -PC  PC  PC  -MC  -PC  MC  ----MC  MC  14  MM-DLBCL  -PC  MC  PC  -PC  PC  PC  PC  PC  PC  MC  -MC  MC  15  MM-DLBCL  -PC  PC  PC  PC  PC  MC  OC  PC  PC  PC  PC  PC  MC  OC  16  PM  -PC  MC  --PC  MC  PC  OC  PC  PC  PC  PC  MC  OC  17  MM-DLBCL  -PC  MC  PC  PC  -PC  PC  PC  PC  PC  PC  PC  MC  PC  18  PM  -MC  --PC  PC  PC  PC  PC  PC  PC  PC  PC  MC  PC  19  MM-DLBCL  -PC  PC  PC  MC  PC  PC  NA  PC  MC  PC  --MC  MC  20  MM-DLBCL  --MC  -MC  --PC  MC  ----MC  MC  21  MM-DLBCL  -PC  PC  --MC  -PC  PC  PC  PC  PC  PC  MC  PC  22  MM-DLBCL  --PC  MC  ---PC  PC  PC  PC  PC  PC  MC  PC  23  PM  --PC  PC  MC  --MC  PC  ----MC  MC  24  PM  -PC  MC  --PC  -PC  PC  PC  PC  PC  PC  MC  PC  25  MM-DLBCL  --PC  --MC  -PC  PC  PC  PC  PC  PC  MC  PC  26  PM  -PC  MC  MC  --PC  PC  PC  PC  PC  PC  MC showed oligoclonal T-cell population ( Table 2 ). The other B-cell post-transplant lymphoproliferative disorders samples, all HIV-associated aggressive B-cell lymphomas, nine of diffuse large B-cell lymphomas in the immune-competent individuals, the 10 cases of reactive lymph nodes and all normal peripheral blood mononuclear cell samples did not show evidence of monoclonal T-cell expansion.
Correlation of the Presence of Monoclonal T-cell Populations in B-cell Post-Transplant Lymphoproliferative Disorders with CD4/CD8 Ratio and Other T-cell Characteristics
All cases of B-cell post-transplant lymphoproliferative disorders with a monoclonal T-cell population showed dominance of CD8-positive cells. Although 9/13 (69%) B-cell post-transplant lymphoproliferative disorders with the presence of monoclonal T-cell population (not including oligoclonal cases) had a CD4:CD8 ratio of r0.4, none of the cases without monoclonal T-cell expansion had a ratio o0.4 (P ¼ 0.002) (Figures 1 and 2 ; Table 3 
Correlation of the Presence of Monoclonal T-cell Populations in B-cell Post-Transplant Lymphoproliferative Disorders with EBV Association
EBV association was present in 20/26 (77%) B-cell post-transplant lymphoproliferative disorders. Although 13/15 (86.7%) B-cell post-transplant lymphoproliferative disorders, which harboured a T-cell clone (including both oligoclonal and monoclonal), were EBV associated, 7/11 (63.6%) samples that lacked T-cell clones showed EBV association. This, however, was statistically not significant (P ¼ 0.618). Seven cases of the 13 (53.8%) EBV-positive B-cell post-transplant lymphoproliferative disorders with associated monoclonal T-cell expansion were analysable by combined immunohistochemistry and in situ hybridisation (with CD3 antibody and EBER probe) and none of them showed EBV positivity in the CD3-positive T-cell population (Figure 2) .
Discussion
This study, to the best of our knowledge, constitutes the largest series of B-cell post-transplant lymphoproliferative disorders investigated for both B-and T-cell clonality. Our results showed that B-cell posttransplant lymphoproliferative disorders harbour secondary clonal populations additional to the preponderant clonal population that is perceived as being 'neoplastic'. Among B-cell post-transplant lymphoproliferative disorders investigated in our study, 88% showed monoclonal B-cell population (100% of monomorphic B-cell post-transplant lymphoproliferative disorders and 78% of polymorphic post-transplant lymphoproliferative disorders) and this is in agreement with other reports in the literature. 19, 20 One-half of B-cell post-transplant lymphoproliferative disorders, all with documented monoclonal B-cell population showed evidence of monoclonal T-cell expansion. The clonal T-cell expansion in two cases was associated with morphological features that could imply coexistence of neoplastic T-cell post-transplant lymphoproliferative disorders or of an early evolution of T-cell post-transplant lymphoproliferative disorders. The coexistence of both B-and T-cell clones in the same lesion has been previously documented in post-transplant lymphoproliferative disorders, but only as case reports. 7, 9 The reports on coexisting B-and T-cell clones include two with metachronous B-cell post-transplant lymphoproliferative disorders and T-cell post-transplant lymphoproliferative disorders, 5, 11 presence of concurrent T-and B-cell post-transplant lymphoproliferative disorders at different sites, 10 simultaneous presence of EBV-positive B-cell posttransplant lymphoproliferative disorders and T-cell post-transplant lymphoproliferative disorders, 6 and a case of cutaneous EBV-driven B-cell posttransplant lymphoproliferative disorders with concomitant peripheral blood T-cell clones. 8 Two cases of EBV-negative cutaneous anaplastic large-cell lymphoma with dual T-and B-cell receptor gene rearrangements have also been reported. 12 Whether the emergence of T-cell clones is triggered by B-cell clones (EBV infected or otherwise) or is secondary to the lack of immune surveillance similar to its impact on EBV-infected B cells is not clear and needs to be elucidated. The lack of immune surveillance secondary to reduced EBVspecific cytotoxic T cells, due to immunosuppressive drugs, is said to play a major role in promoting the development of uncontrolled proliferation of EBV-infected B cells resulting in the development of B-cell post-transplant lymphoproliferative disorders. 14 We speculate that a similar lack of immune surveillance might also be responsible for the emergence of T-cell clones.
All cases of B-cell post-transplant lymphoproliferative disorders with a monoclonal T-cell population showed a significant predominance of CD8-positive cells. The finding needs to be further documented using laser capture microdissection to assess the clonality of isolated CD8-positive cells in cases with T-cell clonal expansion or in sorted T-cell subpopulations if fresh tissue is available. Whether an infective agent directly infecting the T cells plays a role is difficult to substantiate. Among our cases, we found that a majority of B-cell post-transplant lymphoproliferative disorders (77%) have CD8-positive T cells in excess of CD4-positive T cells in the microenvironment. Literature available on this aspect of post-transplant lymphoproliferative disorders is limited. In a small series, it was reported in 1998 that CD4-positive cells predominated over CD8-positive cells among 8/11 post-transplant lymphoproliferative disorders samples. 21 There has been an occasional report associating the existence of oligoclonal cytotoxic T-cell populations with tumour regression in post-transplant lymphoproliferative disorders. 22 More recently, higher numbers of tumour-infiltrating T cells and TIA-1 þ (T-cell intracellular antigen-1) cytotoxic T cells have been reported to be predictors of favourable outcome in post-transplant lymphoproliferative disorders patients indicating the preservation of antitumour immune responses in these patients. 23 We excluded the possibility of EBV infecting and driving the T cells. EBV has been found to infect a subset of T cells that express the viral receptor CD21. 4 High levels of uncontrolled viral replication are thought to facilitate the entrance of EBV into T cells. 5 Despite the presence of previous reports, which showed that EBV can infect T cells, in our study none of the seven assessable cases showed evidence of EBV infection in the T-cell population.
In the first five years of transplantation, EBVpositive post-transplant lymphoproliferative disorders predominate over EBV-negative B-cell post-transplant lymphoproliferative disorders. Furthermore, a greater proportion of late-onset B-cell post-transplant lymphoproliferative disorders are EBV negative, and most T-cell post-transplant lymphoproliferative disorders are late onset. 12, [24] [25] [26] Hence, in the posttransplant setting, EBV-infected B cells appear to have a proliferative advantage.
The presence of 'benign' clonally expanded T cells or T cells demonstrating skewed T-cell receptor repertoire in the peripheral blood is known in patients following transplantation. Among patients who have had allogenic stem cell transplantation, these T cells are of donor origin and are likely to be induced by EBV-infected B cells. 27 On the other hand, in patients of solid organ transplants like renal transplants, the T cells are of patient/ recipient origin and represent allo-reactive T cells against the transplanted organ. The presence of expanded T-cell clones in the peripheral blood has been shown to have a negative impact on the long-term graft function (survival of the transplanted kidney). 28 Contrary to post-transplant lymphoproliferative disorders, we did not encounter a single case of HIVassociated aggressive B-cell lymphomas with the presence of T-cell clones. During the early course of HIV-1 infection, CD8-positive T cells show a moderate rise, which is transient in most cases, and then decline in parallel with the depletion of CD4-positive T cells. 29 However, persistent elevation of circulating CD8-positive T cells with visceral involvement, mainly salivary glands and lung, in response to HIV-1 infection, has been described in certain group of patients. 30 These are manifested as clonally expanded T-cell populations in the peripheral blood and in the viscera. The clonal expansions can be large and may persist with dominance of specific clones. [31] [32] [33] [34] In summary, our results show that monoclonal expansion of T-cell population occurs frequently in B-cell post-transplant lymphoproliferative disorders and these clonal T-cell populations coexist with monoclonal B-cell population in B-cell posttransplant lymphoproliferative disorders. The T-cell clones seem to arise mainly from CD8-positive T cells. Whether EBV plays a pivotal role in the emergence of T-cell clones is unclear. It is intuitive to think that EBV and other infective agents possibly play a role in the clonal expansion of CD8-positive T cells. Although the monoclonal T-cell population is cytomorphologically occult in most, rare cases with the presence of morphological atypia may suggest a potential to progression. In such cases, follow-up and clinical correlation could be recommended. More studies are required to validate these findings.
